Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luvometinib + Modified LCH-III in Pediatric Multisystem LCH
NCT07431060Recruiting
- Sponsor
- West China Second University Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of luvometinib in Langerhans cell histiocytosis (LCH) (2 arms), sponsored by West China Second University Hospital. Primary endpoint: Event-Free Survival up to 2 years. Started Feb 2026; status: recruiting.
02
Drugs
luvometinib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT07431060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07431060.